Press Room
  Date Title View
Feb 21, 2017
FOSTER CITY, Calif., Feb. 21, 2017 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the fourth quarter and full year 2016 on Monday, March 6, 2017. SciClone will host a conference call and webcast to provide a business update at 8:30 am ET (5:30 am PT) that day. The call wil...
PDF
Feb 1, 2017
FOSTER CITY, Calif., Feb. 1, 2017 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., Chief Executive Officer, will present a corporate overview and business update at the 19th Annual BIO CEO & Investor Conference at 4:30 pm ET on Monday, February 13, 2017, at the Waldorf Astoria Hotel in New ...
PDF
Nov 14, 2016
FOSTER CITY, Calif., Nov. 14, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) ("SciClone") today confirmed that it has received an unsolicited, nonbinding proposal from a consortium led by GL Capital Management GP Limited and ABG Management Limited to acquire all of the outstanding shares of SciClone not already owned by the cons...
PDF
Nov 9, 2016
FOSTER CITY, Calif., Nov. 9, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the quarter ended September 30, 2016. Revenues: In the third quarter of 2016, SciClone reported revenues of $40.5 million, compared to $42.9 million for the same period in 2015. GAAP Diluted EPS: In...
PDF
Oct 25, 2016
FOSTER CITY, Calif., Oct. 25, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the third quarter 2016 on Wednesday, November 9, 2016. SciClone will host a conference call and webcast to provide a business and product update at 4:30 pm ET (1:30 pm PT) that day. The call ...
PDF
Sep 26, 2016
FOSTER CITY, Calif., Sept. 26, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced two important achievements in advancing the Company's clinical pipeline and development portfolio in Greater China. The first patient has been treated in the Phase 3 trial of ZADAXIN® in sepsis, a life-threatening infectious diseas...
PDF
Sep 12, 2016
PRINCETON, N.J. and FOSTER CITY, Calif., Sept. 12, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, and SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN), a US-based China-focused specialty pharmaceut...
PDF
Sep 1, 2016
FOSTER CITY, Calif., Sept. 1, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the Company will present a corporate overview and business update at two investor conferences in September 2016. Friedhelm Blobel, PhD, Chief Executive Officer, will present at the Rodman & Renshaw 18th Annual Global ...
PDF
Aug 9, 2016
FOSTER CITY, Calif., Aug. 9, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the quarter ended June 30, 2016.   Revenues: In the second quarter of 2016, SciClone reported revenues of $39.0 million, compared to $37.9 million for the same period in 2015. GAAP Diluted EP...
PDF
Jul 28, 2016
FOSTER CITY, Calif., July 28, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the second quarter 2016 on Tuesday, August 9, 2016. SciClone will host a conference call and webcast to provide a business and product update at 4:30 pm ET (1:30 pm PT) that day. The call wil...
PDF
1
...
NextLast